L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin

被引:35
作者
Clair T. [1 ]
Koh E. [1 ]
Ptaszynska M. [1 ]
Bandle R.W. [1 ]
Liotta L.A. [1 ]
Schiffmann E. [1 ]
Stracke M.L. [1 ]
机构
[1] Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda
关键词
Histidine; A2058 Cell; Metal Cation; Motility Assay; Histidinol;
D O I
10.1186/1476-511X-4-5
中图分类号
学科分类号
摘要
Background: Autotaxin (ATX, NPP-2), originally purified as a potent tumor cell motility factor, is now known to be the long-sought plasma lysophospholipase D (LPLD). The integrity of the enzymatic active site, including three crucial histidine moieties, is required for motility stimulation, as well as LPLD and 5′nucleotide phosphodiesterase (PDE) activities. Except for relatively non-specific chelation agents, there are no known inhibitors of the ATX LPLD activity. Results: We show that millimolar concentrations of L-histidine inhibit ATX-stimulated but not LPA-stimulated motility in two tumor cell lines, as well as inhibiting enzymatic activities. Inhibition is reversed by 20-fold lower concentrations of zinc salt. L-histidine has no significant effect on the Km of LPLD, but reduces the Vmax by greater than 50%, acting as a non-competitive inhibitor. Several histidine analogs also inhibit the LPLD activity of ATX; however, none has greater potency than L-histidine and all decrease cell viability or adhesion. Conclusion: L-histidine inhibition of LPLD is not a simple stoichiometric chelation of metal ions but is more likely a complex interaction with a variety of moieties, including the metal cation, at or near the active site. The inhibitory effect of L-histidine requires all three major functional groups of histidine: the alpha amino group, the alpha carboxyl group, and the metal-binding imidazole side chain. Because of LPA's involvement in pathological processes, regulation of its formation by ATX may give insight into possible novel therapeutic approaches. © 2005 Clair et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 35 条
[21]  
Sytkowski A.J., Vallee B.L., The catalytic metal atoms of cobalt substituted liver alcohol dehydrogenase, Biochem Biophys Res Commun, 67, 4, pp. 1488-1493, (1975)
[22]  
Chu Y., Lee E.Y., Reimann E.M., Wilson S.E., Schlender K.K., Effect of activation of protein phosphatase 1 on sulfhydryl reactivity, Arch Biochem Biophys, 334, 1, pp. 83-88, (1996)
[23]  
Cha M.H., Yong W.M., Lee S.M., Lee Y.S., Chung I.Y., The biochemical and molecular characterization of recombinant Bacillus subtilis tripeptidase (PepT) as a zinc-dependent metalloenzyme, Mol Cells, 10, 4, pp. 423-431, (2000)
[24]  
Kuzuya K., Inouye K., Effects of cobalt-substitution of the active zinc ion in thermolysin on its activity and active-site microenvironment, J Biochem (Tokyo), 130, 6, pp. 783-788, (2001)
[25]  
McMillen L., Beacham I.R., Burns D.M., Cobalt activation of Escherichia coli 5′-nucleotidase is due to zinc ion displacement at only one of two metal-ion-binding sites, Biochem J, 372, 2 PART, pp. 625-630, (2003)
[26]  
Galperin M.Y., Bairoch A., Koonin E.V., A superfamily of metalloenzymes unifies phosphopentomutase and cofactor-independent phosphoglycerate mutase with alkaline phosphatases and sulfatases, Protein Sci, 7, 8, pp. 1829-1835, (1998)
[27]  
Sytkowski A.J., Vallee B.L., Chemical reactivities of catalytic and noncatalytic zinc or cobalt atoms of horse liver alcohol dehydrogenase: Differentiation by their thermodynamic and kinetic properties, Proc Natl Acad Sci U S A, 73, 2, pp. 344-348, (1976)
[28]  
Puerta D.T., Lewis J.A., Cohen S.M., New beginnings for matrix metalloproteinase inhibitors: Identification of high-affinity zincbinding groups, J Am Chem Soc, 126, 27, pp. 8388-8389, (2004)
[29]  
Moolenaar W.H., Van Meeteren L.A., Giepmans B.N., The ins and outs of lysophosphatidic acid signaling, Bioessays, 26, 8, pp. 870-881, (2004)
[30]  
Nam S.W., Clair T., Campo C.K., Lee H.Y., Liotta L.A., Stracke M.L., Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells, Oncogene, 19, 2 JANUARY 13, pp. 241-2247, (2000)